{
  "id": 13931865,
  "title": "Dr. Lal PathLabs Invests Up To ₹30.3 Crore In Wholly Owned Subsidiary PUPL",
  "url": "https://urgent.news/2026/10/12/dr-lal-pathlabs-invests-up-to-30-3-crore-in-wholly-owned-subsidiary",
  "topic": "business",
  "section": "Business",
  "published": "2026-10-12T10:19:11.000Z",
  "source": {
    "name": "Free Press Journal",
    "slug": "free-press-journal",
    "url": "https://www.freepressjournal.in/business/dr-lal-pathlabs-invests-up-to-303-crore-in-wholly-owned-subsidiary-pupl"
  },
  "original_language": "en",
  "account": "Dr. Lal PathLabs announced an investment of up to ₹30.3 crore in its wholly-owned subsidiary, PathLabs Unifiers Private Limited (PUPL), on October 12, 2026. PUPL will remain a wholly-owned subsidiary following this transaction. The funds will be used to buy the remaining 30% stake of CentraPath Labs Private Limited (CPL), making CPL a wholly-owned subsidiary of PUPL. Dr. Lal PathLabs already holds an 80% stake in Ghana's Sunshine Healthcare subsidiary. PUPL, founded on December 12, 2018, operates in the healthcare and diagnostics sector. The investment is considered a related party transaction, but Dr Lal PathLabs confirmed it was conducted on an arm's length basis.",
  "summary": "Mumbai: Dr. Lal PathLabs Limited on Friday announced a further investment in its wholly owned subsidiary, PathLabs Unifiers Private Limited (PUPL), by subscribing to equity shares on October 12, 2026. Investment Details The investment involves a cash consideration not exceeding ₹30.3 crore. PUPL will continue to operate as a wholly owned subsidiary of Dr. Lal PathLabs following this transaction.…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}